Clinical Trial Update: Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study [Phase 2]

View source ↗

Summary

Phase 2 trial update on iron chelation therapy for myelodysplastic syndromes with event-free survival data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Iron chelation therapy

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2020-11-23